OOIR: Observatory of International Research

Papers

(The TQCC of Leukemia & Lymphoma is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy	57
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome	34
Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype	33
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and ‘bridge’ to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma	31
Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia	30
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy	30
Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma	28
Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a	24
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	24
Polatuzumab vedotin extravasation injury: a case report	22
Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia	22
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated bod	22
Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutat	21
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	20
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?	20
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim ¹⁸ F-FDG PET/CT scans	19
Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center	19
Efficacy of lenalidomide in a patient with systemic mastocytosis associated withSF3B1-mutant myelodysplastic syndrome	18
At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China	17
The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma	17
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	17
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	16
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia	16
Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient	16
CD5+ diffuse large B-cell lymphoma: a narrative review	15

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival	15
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)	15
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)	15
CD22 expression in acute myeloid leukemia: close correlation with interleukin-2 receptor α-chain (CD25) expression and poor prognosis	15
Molecular- and cytogenetic characterization of the IGH associated t(1;14) in a nodal marginal zone B-cell lymphoma case	14
Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical	14
Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP	14
The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease	14
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design	14
Post PARP inhibitor therapy-related acute megakaryoblastic leukemia in a patient with germline BRCA1-mutated high-grade serous ovarian carcinoma	14
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	14
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia	13
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete em	13
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression	13
Transcriptional deregulation of LSD1 and LSD2 is associated with cytogenetic risk in chronic lymphocytic leukemia	13
Classic Hodgkin lymphoma cloaked in an intense sarcoid-like reaction	13
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center	13
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	12
Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation	12
Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma	12
Post-transplant maintenance therapy for MDS and AML: a bridge too far or the beginning of a new era?	12
Uncommon histiocyte-rich pseudotumor after chemotherapy in peripheral T-cell lymphoma	12
Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience	12
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	12
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset	11
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	11
Real-world assessment of isocitrate dehydrogenase inhibitor-associated differentiation syndrome	11
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	11
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis	11
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	11
Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission	11
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	11
Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak	11
Smoldering multiple myeloma: biology, clinical manifestations and management	11
Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001–2016: a Danish nationwide cohort study	11
Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase	11
The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia	11
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	10
Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation	10
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	10
Severe lympho-depletion, abrogated thymopoiesis and systemic EBV positive T-cell lymphoma of childhood, a case	10
Targets and treatments in primary CNS lymphoma	10
Management of relapsed/refractory mantle cell lymphoma	10
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia	10
Response to ‘blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives’	10
The value of bispecific antibodies in relapsed and refractory DLBCL	10
Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens – pilot study	10
Prognostic significance of copy number gains of MYC detected by fluorescence in situ hybridization in large B-cell lymphoma	10
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	10
Epidemiology and survival of primary extraosseous plasmacytoma: insights from a population-based study with a 20-year follow-up	9

Results with allo-SCT in patients with relapsed/refractory HL treated with anti-PD-1, a multicenter retrospective cohort study: subcommittee of transplantation and cellular therapy (GATMO-TC) of the A	9
Thromboprophylaxis in multiple myeloma	9
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	9
Smoldering multiple myeloma: Reviewing the rationale for intervention	9
Optimal dosing of cytarabine in childhood acute myeloid leukemia: do we have the answer yet?	9
Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma	9
Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis	9
Post CAR-T cytopenia: poorly understood and clinically challenging	9
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML	9
Prognostic significance of NOTCH1/FBXW7 mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol	9
Norovirus and sapovirus infections after allogeneic hematopoietic stem cell transplantation: is it worth it to look for them?	9
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	9
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	9
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy	9
Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis	9
Organ toxicities associated with chimeric antigen receptor T-cell therapy	9
Infusion of haploidentical NKG2D-CAR-T_CD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits	9
Safe administration of obinutuzumab to rituximab-intolerant patients	8
Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison	8
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	8
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant	8
Should WE use flow cytometry to assess bone marrow involvement by lymphoma?	8
Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation	8
A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia	8
XX International workshop on chronic lymphocytic leukemia	8
JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options	8
Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations	8
African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center	8
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	8
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	8
Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration	8
Putting the brain into mantle cell lymphoma	8
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	8
Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada	8
Impact of SF3B1 mutation in myelofibrosis	8
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	8
Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome	8
Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome	8
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma	8
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	8
Imaging minimal residual disease evaluation in multiple myeloma using [ ¹⁸ F]FDG PET/MRI	8
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation	7
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple m	7
Recent advances in the treatment of polycythemia vera	7
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma	7
CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies	7
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	7
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia	7
lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p	7
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma	7
Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population	7
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available	7
Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia	7
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	7
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements	7
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	7
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	7
IDH2 mutations in acute myeloid leukemia	7
Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies	7
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	7
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	7
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy	7
Curative intent therapy for DLBCL in the elderly	7
Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation	7
Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide	7
Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experience	7
Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy	7
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	7
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents	7
Multi-site pre-therapeutic biopsies demonstrate genetic heterogeneity in patients with newly diagnosed diffuse large B-cell lymphoma	7
CD38 as a multifaceted immunotherapeutic target in CLL	7
Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia	7
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients	7
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation	7
Role of high acquisition flow cytometry in the detection of marrow involvement in patients with extramedullary B cell non-Hodgkins lymphoma: a comparison with marrow aspirate cytology, trephine biopsy	7
Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors	7
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing	7
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data	7
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	6
Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center	6

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies	6
Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma	6
FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement	6
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	6
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis	6
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	6
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation	6
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	6
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	6
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	6
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	6
Transplantation provides superior survival high risk myeloid malignancies in older patients	6
Mutations known from B-cell lymphoid malignancies are not found in CD34 ⁺ stem cells from patients with lymphoma	6
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment	6
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	6
Radiation therapy for the management of T cell cutaneous lymphomas. Updated results of the role of low dose total skin electron beam (TSEB) therapy	6
ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies	6
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	6
Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL	6
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	6
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	6
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	6
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?	6
Primary central nervous system lymphoma in children - a rare but serious disease with good prognosis from a single center in China	6
Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia	6
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	6
Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia	6
Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient	6
High-dose methotrexate dosing strategy in primary central nervous system lymphoma	6
Searching for germline mutations in the RUNX1 gene among Polish patients with acute myeloid leukemia	6
The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL	5
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib	5
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia	5
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	5
Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab	5
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	5
Correction	5
Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy	5
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	5
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	5
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial	5
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
Predicting relapse in acute lymphoblastic leukemia	5
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	5
Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications	5
Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature	5
Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices	5
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	5
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from	5
Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma	5
Clinically appropriate dose reductions and interruptions do not compromise efficacy in patients receiving treatment with ibrutinib	5
Correction	5
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	5
Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester	5
Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia	5
Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients	5
A case report of solitary presentations of large B-cell lymphoma of immune-privileged sites (IP-LBCL) in the testis, vitreous body, and skin	5
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review	5
NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980–2017: a nationwide cohort study	5
What constitutes meaningful improvement in myelodysplastic syndromes?	5
Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity	5
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	5
Attempted desensitization to calaspargase pegol: a familiar approach to a new problem	5
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	5
Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia	5
Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center	5
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	5
Correction	5
Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy	5
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation	5
Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells via modulation of NF-κB, AP-1, and Akt signaling	5
Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data	5
A retrospective analysis of factors impacting survival in United States military veterans with multiple myeloma	5
Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on tyrosine kinase inhibitor therapy	5
Very low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue	5
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
Correction	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
Clinicopathologic characteristics of de novo NF1 -mutated acute myeloid leukemia	5
Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment	4
Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study	4
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	4
Responsible enzymes for metabolizing vitamin D in patients with acute leukemia and the relationship with treatment outcomes: a case-control study	4
Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing	4
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	4
The broader prospects for bispecifics in Hodgkin lymphoma	4
Early prediction of stable MR^4.5 by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib	4
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?	4
Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma	4
Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab	4
SNP-based chromosomal microarray characterization in a series of pure erythroid leukemia	4